Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol for SHPT in CKD Stages 3-4
NCT04994080Phase 3Unknown
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of paricalcitol in secondary hyperparathyroidism (SHPT), sponsored by Chengdu Suncadia Pharmaceuticals. Status: unknown.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT04994080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994080.